Hepion Pharmaceuticals Inc. (NASDAQ: HEPA) is 5.48% higher on its value in year-to-date trading and has touched a low of $1.00 and a high of $5.22 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The HEPA stock was last observed hovering at around $2.20 in the last trading session, with the day’s gains setting it 0.11% off its average median price target of $8.00 for the next 12 months. It is also 71.13% off the consensus price target high of $8.00 offered by 1 analysts, but current levels are 71.13% higher than the price target low of $8.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $2.31, the stock is -3.00% and 5.39% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 21.31 million and changing 5.00% at the moment leaves the stock -16.60% off its SMA200. HEPA registered -53.24% loss for a year compared to 6-month loss of -37.57%. The firm has a 50-day simple moving average (SMA 50) of $2.3182 and a 200-day simple moving average (SMA200) of $2.7747.
The stock witnessed a 0.43% gain in the last 1 month and extending the period to 3 months gives it a -13.81%, and is -18.66% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.98% over the week and 9.33% over the month.
Distance from 52-week low is 131.00% and -55.75% from its 52-week high.
Hepion Pharmaceuticals Inc. (HEPA) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Hepion Pharmaceuticals Inc. (HEPA) is a “Buy”. 1 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Hepion Pharmaceuticals Inc. is expected to release its quarterly report on 05/18/2021 and quarterly earnings per share for the current quarter are estimated at -$0.38.The EPS is expected to grow by 93.70% this year.
Hepion Pharmaceuticals Inc. (HEPA) Top Institutional Holders
27 institutions hold shares in Hepion Pharmaceuticals Inc. (HEPA), with 350.08k shares held by insiders accounting for 3.88% while institutional investors hold 14.34% of the company’s shares. The shares outstanding are 9.03M, and float is at 9.02M with Short Float at 2.97%. Institutions hold 13.78% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 1.19 million shares valued at $2.62 million. The investor’s holdings represent 13.23% of the HEPA Shares outstanding. As of Dec 30, 2020, the second largest holder is Renaissance Technologies, LLC with 0.33 million shares valued at $0.72 million to account for 3.65% of the shares outstanding. The other top investors are Perkins Capital Management, Inc. which holds 0.15 million shares representing 1.66% and valued at over $0.33 million, while Gsa Capital Partners Llp holds 0.99% of the shares totaling 89067.0 with a market value of $0.2 million.
Hepion Pharmaceuticals Inc. (HEPA) Insider Activity
A total of 8 insider transactions have happened at Hepion Pharmaceuticals Inc. (HEPA) in the last six months, with sales accounting for 0 and purchases happening 8 times. The most recent transaction is an insider purchase by Cavan John T, the company’s Chief Financial Officer. SEC filings show that Cavan John T bought 10,000 shares of the company’s common stock on Feb 18 at a price of $2.00 per share for a total of $20000.0. Following the purchase, the insider now owns 14800.0 shares.
Hepion Pharmaceuticals Inc. disclosed in a document filed with the SEC on Feb 18 that Foster Robert T (CEO and Director) bought a total of 20,000 shares of the company’s common stock. The trade occurred on Feb 18 and was made at $2.00 per share for $40000.0. Following the transaction, the insider now directly holds 45259.0 shares of the HEPA stock.
Still, SEC filings show that on Feb 16, Wijngaard Peter (Director) acquired 10,000 shares at an average price of $2.20 for $22000.0. The insider now directly holds 30,000 shares of Hepion Pharmaceuticals Inc. (HEPA).